Emer­gent TV ads book­end its tu­mul­tuous year. Can mil­i­tary, Nar­can work help re­hab its brand?

When the Covid-19 pan­dem­ic hit, Emer­gent BioSo­lu­tions was rel­a­tive­ly un­known. But the con­tract de­vel­op­ment and man­u­fac­tur­ing or­ga­ni­za­tion (CD­MO) sud­den­ly hit the spot­light when it nabbed a mas­sive $628 mil­lion gov­ern­ment deal in mid-2020 to man­u­fac­ture John­son & John­son and As­traZeneca Covid-19 vac­cines.

Emer­gent saw an op­por­tu­ni­ty to in­tro­duce the pub­lic to its brand. Along with its CD­MO work, Emer­gent makes its own vac­cines and com­mer­cial meds, in­clud­ing the Nar­can opi­oid re­ver­sal agent, as well as med­ical coun­ter­mea­sure prod­ucts like small­pox and an­thrax vac­cines.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN